Chemokine Profile and the Alterations in CCR5-CCL5 Axis in Geographic Atrophy Secondary to Age-Related Macular Degeneration.


Journal

Investigative ophthalmology & visual science
ISSN: 1552-5783
Titre abrégé: Invest Ophthalmol Vis Sci
Pays: United States
ID NLM: 7703701

Informations de publication

Date de publication:
09 04 2020
Historique:
entrez: 24 4 2020
pubmed: 24 4 2020
medline: 29 8 2020
Statut: ppublish

Résumé

Geographic atrophy (GA) secondary to age-related macular degeneration (AMD) is a progressive disease with no treatment option. Previous studies show chemokine-mediated recruitment of immune cells in the retina, and therefore we investigated systemic levels of chemokines and chemokine receptors in patients with GA. This observational prospective study was conducted at a single center. We included 122 participants with no immune disease: 41 participants with GA and no choroidal neovascularization, 51 patients with neovascular AMD, and 30 healthy control individuals. Flow cytometric analysis was used to detect expression level of C-C chemokine receptor (CCR)1, CCR2, CCR3, CCR5, and C-X-C motif chemokine receptor (CXCR)3 on peripheral blood mononuclear cells (CD14+ monocytes, CD4+ T cells, CD8+ T cells). Plasma levels of C-C motif ligand (CCL)11, C-X-C motif chemokine (CXCL)10, and CCL5 were measured by specific immunoassays. Enlargement rate of GA lesion was measured from autofluorescence images. Participants with GA have a specific chemokine profile with a higher expression of CCR5 than healthy controls in peripheral blood mononuclear cells, and a higher plasma levels of CCL-5. Further, GA was associated with higher monocytic expression of CCR2 than in neovascular AMD. We found that a high expression level of CCR5 on CD8+ T cells was associated with slower enlargement rate of atrophic lesion. The study showed an association between systemic chemokine profile and GA formation. Further studies are needed to fully elucidate the possible role of systemic chemokine regulation in mediating pathogenesis of GA.

Identifiants

pubmed: 32324857
pii: 2765166
doi: 10.1167/iovs.61.4.28
pmc: PMC7401724
doi:

Substances chimiques

CCR5 protein, human 0
Chemokine CCL5 0
Receptors, CCR5 0
Vascular Endothelial Growth Factor A 0

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

28

Références

Birth Defects Res C Embryo Today. 2012 Dec;96(4):325-33
pubmed: 24203921
Graefes Arch Clin Exp Ophthalmol. 2015 Nov;253(11):1941-5
pubmed: 26148801
J Neurosci. 2008 Nov 12;28(46):11980-8
pubmed: 19005063
Annu Rev Immunol. 2014;32:659-702
pubmed: 24655300
J Neuroimmunol. 2006 Oct;179(1-2):132-44
pubmed: 16857269
Shock. 2019 Nov;52(5):e100-e106
pubmed: 30724784
Blood. 2003 Jun 1;101(11):4253-9
pubmed: 12560237
J Clin Invest. 2007 Oct;117(10):2920-8
pubmed: 17909628
Clin Exp Ophthalmol. 2019 Jan;47(1):69-78
pubmed: 30047199
Dan Med J. 2016 Nov;63(11):
pubmed: 27808038
Prog Retin Eye Res. 2017 Nov;61:98-128
pubmed: 28602950
PLoS One. 2012;7(9):e44834
pubmed: 23028638
Cell Immunol. 2006 Sep;243(1):19-29
pubmed: 17257590
Nature. 2009 Jul 9;460(7252):225-30
pubmed: 19525930
Aging Dis. 2015 Nov 17;6(6):444-55
pubmed: 26618046
Neurobiol Dis. 2011 Apr;42(1):55-72
pubmed: 21220018
Invest Ophthalmol Vis Sci. 2019 Jan 2;60(1):202-208
pubmed: 30644965
Invest Ophthalmol Vis Sci. 2013 Mar 28;54(3):1905-12
pubmed: 23404120
J Immunol. 2010 Apr 15;184(8):4079-86
pubmed: 20212096
Ageing Res Rev. 2011 Jul;10(3):319-29
pubmed: 21145432
PLoS One. 2012;7(7):e40812
pubmed: 22815829
Invest Ophthalmol Vis Sci. 2012 Aug 07;53(9):5292-300
pubmed: 22789920
Trans Am Ophthalmol Soc. 2009 Dec;107:311-24
pubmed: 20126505
Cell Immunol. 1998 Feb 25;184(1):37-44
pubmed: 9626333
Neurobiol Aging. 2010 Jan;31(1):8-16
pubmed: 18440671
Acta Ophthalmol. 2017 Aug;95(5):472-480
pubmed: 27860298
Clin Chem. 2001 Jan;47(1):28-30
pubmed: 11148173
Ophthalmology. 2006 Feb;113(2):260-6
pubmed: 16458093
Acta Ophthalmol. 2019 Feb;97(1):99-106
pubmed: 30288946
Neurobiol Dis. 2013 Jan;49:159-68
pubmed: 22922220
Invest Ophthalmol Vis Sci. 2014 May 08;55(7):4050-6
pubmed: 24812555
Neurobiol Aging. 2016 Apr;40:110-119
pubmed: 26973110
J Exp Med. 2006 Jan 23;203(1):35-40
pubmed: 16418398
Lancet Glob Health. 2014 Feb;2(2):e106-16
pubmed: 25104651
Proc Natl Acad Sci U S A. 1998 Nov 24;95(24):14500-5
pubmed: 9826729
Exp Eye Res. 2008 Apr;86(4):675-83
pubmed: 18308304
Nat Rev Neurol. 2016 Feb;12(2):95-105
pubmed: 26782333
EMBO Mol Med. 2013 Nov;5(11):1775-93
pubmed: 24142887
Acta Neurol Scand. 2007 Dec;116(6):374-9
pubmed: 17986095
Methods Mol Biol. 2013;1013:1-16
pubmed: 23625489
Ophthalmic Res. 2015;53(1):2-7
pubmed: 25472810

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH